Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 2/20 | 0.56 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.52 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.52 |
| ▸ | HTR3B | O95264 | 2/20 | 0.52 |
| ▸ | HTR3A | P46098 | 2/20 | 0.52 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.52 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.51 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.51 |
| ▸ | IDO1 | P14902 | 4/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | AGXT | P21549 | 2/20 | 0.50 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12345478 | 0.83 | MAOB (0.39) | CHRM2CHRM1CHRM3LMNA | |
| SCHEMBL11044554 | 0.82 | IDO1 (0.47) | PNMTTAAR1HTR3EHTR3BHTR3A | |
| SCHEMBL67484 | 0.81 | TAAR1 (0.57) | PNMTTAAR1HTR3EHTR3BHTR3A | |
| SCHEMBL27603356 | 0.81 | IDO1 (0.50) | PNMTTAAR1HTR3EHTR3BHTR3A | |
| SCHEMBL28001311 | 0.81 | IDO1 (0.46) | PNMTTAAR1HTR3EHTR3BHTR3A | |
| SCHEMBL3084924 | 0.80 | PNMT (0.54) | PNMTTAAR1HTR3EHTR3BHTR3A | |
| SCHEMBL6083088 | 0.80 | HTR3E (0.55) | PNMTTAAR1HTR3EHTR3BHTR3A | |
| SCHEMBL28879871 | 0.80 | PNMT (0.54) | PNMTTAAR1HTR3EHTR3BHTR3A | |
| SCHEMBL771274 | 0.80 | PNMT (0.54) | PNMTTAAR1HTR3EHTR3BHTR3A | |
| SCHEMBL7481246 | 0.80 | PNMT (0.59) | PNMTTAAR1HTR3EHTR3BHTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 197 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112225713-B | Synthesis process of 5-hydroxybenzofuran compound | 华东理工大学 | 2023-02-28 | — | — | CN | claimed |
| CN-112225713-A | Synthesis process of 5-hydroxybenzofuran compound | 华东理工大学 | 2021-01-15 | — | — | CN | claimed |
| EP-4294800-B1 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS INC (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20260103491-A1 | ARYL SUBSTITUTED POLYMYXIN DERIVATIVES | SPERO THERAPEUTICS INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-20260055083-A1 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-12528837-B2 | Aryl substituted polymyxin derivatives | SPERO THERAPEUTICS, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| EP-4573077-A1 | APOL1 INHIBITORS AND METHODS OF USE | Maze Therapeutics, Inc. (US) | 2025-06-25 | — | — | EP | disclosed |
| WO-2024249252-A1 | METHODS OF USING APOL1 INHIBITORS | MAZE THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | WO | disclosed |
| CN-118878638-A | Polymyxin compound, pharmaceutical composition and application thereof | 云顶新耀医药科技有限公司 | 2024-11-01 | — | — | CN | disclosed |
| US-20240316038-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2024-09-26 | — | — | US | disclosed |
| CN-112789287-B | Compounds of formula (I) | 云顶新耀医药科技有限公司 | 2024-06-21 | — | — | CN | disclosed |
| EP-0114374-B1 | SUBSTITUTED 4-AMINOMETHYLENE CHROMANS OR CHROMENES, PROCESS FOR THEIR PREPARATION AND THEIR USE IN MEDICINES | BAYER AG (DE) | 1986-07-23 | — | — | EP | disclosed |
| US-4563458-A | CIRCULATORY SYSTEM DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 1986-01-07 | — | — | US | disclosed |
| EP-0158164-A2 | Substituted 4-hydroxy-benzopyrans, process for their preparation and their use in medicines | BAYER AG (DE) | 1985-10-16 | — | — | EP | disclosed |
| EP-0109679-B1 | PROCESS FOR THE SIMULTANEOUS PRODUCTION OF PHENYLACETATE ESTERS AND PHENYLACETALDEHYDES | DENKI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1985-08-14 | — | — | EP | disclosed |
| EP-0114374-A1 | Substituted 4-aminomethylene chromans or chromenes, process for their preparation and their use in medicines | BAYER AG (DE) | 1984-08-01 | — | — | EP | disclosed |
| EP-0109679-A1 | Process for the simultaneous production of phenylacetate esters and phenylacetaldehydes | DENKI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1984-05-30 | — | — | EP | disclosed |
| US-4267359-A | Novel carboxylic acid esters | ZOECON CORPORATION (US) | 1981-05-12 | — | — | US | disclosed |
| US-4204071-A | 4-Aryl-3-butenoic acids and lower alkyl esters | ZOECON CORPORATION (US) | 1980-05-20 | — | — | US | disclosed |
| US-3984400-A | 11-Desoxy-16-aryl-ω-tetranorprostaglandins | PFIZER INC. (US) | 1976-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12528837-B2 | Aryl substituted polymyxin derivatives | PTMS, PNISR, BCAT2 | PNMT 135/4885TAAR1 1948/4885HTR3E 2694/4885 |
| US-20260103491-A1 | ARYL SUBSTITUTED POLYMYXIN DERIVATIVES | PTMS, FPR1, BCAT2 | PNMT 114/4885TAAR1 1354/4885HTR3E 2892/4885 |
| US-20260055083-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, LDLR, APOB | PNMT 4822/4885TAAR1 1185/4885HTR3E 2157/4885 |
| US-20240316038-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, SAAL1, APOB | PNMT 4753/4885TAAR1 2197/4885HTR3E 3349/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.